Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Igalmi™ (dexmedetomidine) – New drug approval
April 6, 2022 - BioXcel Therapeutics announced the FDA approval of Igalmi (dexmedetomidine), for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
